Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial
PaperCitations, authors & open-access status
Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 96 citations, 2024 year and green oa status.
96
Citations
2024
Year
green
OA Status